#China #Shanghai #WuXi Biologics #Drug Product #GMP Facility

WuXi Biologics Enhances Drug Product Capabilities

WuXi Biologics, a prominent global Contract Research, Development and Manufacturing Organization (CRDMO), has recently announced the GMP release of its 18th operational drug product facility, DP15, located at its Fengxian site in Shanghai. This milestone, achieved in April, signifies a major advancement in WuXi's integrated capabilities, transitioning drug substances into actual drug products efficiently.

The DP15 facility is designed and constructed to comply with international regulatory standards, offering significant flexibility and operational efficiency to cater to clinical-stage programs. This state-of-the-art facility is equipped with advanced isolator-based aseptic filling lines, facilitating the manufacturing of both liquid and lyophilized drug products. Notable features include a 100% fill weight check, nitrogen overlay, and low-temperature loading for lyophilization, enabling the production of a diverse range of vial sizes from 2R to 20R.

Improving Timelines and Deliverables

As the demand for biologics continues to rise, WuXi Biologics has positioned DP15 to enhance the transition from development to GMP manufacturing. The facility's seamless integration with existing site operations aims to accelerate project timelines, thereby providing quicker and more efficient delivery for its clients. According to Dr. Chris Chen, CEO of WuXi Biologics, this development reinforces the company's commitment to enabling partners to shorten technology transfer timelines and improve execution efficiency for critical development milestones.

WuXi Biologics has already made significant contributions to the biopharmaceutical industry, delivering over 2,350 drug substance batches and more than 2,260 drug product batches by the end of 2025. Furthermore, the company has successfully passed 46 regulatory inspections, maintaining an impressive record with no critical findings or data integrity issues. This success underscores their commitment to quality and reliability in manufacturing processes.

Global Integrated Service Platform

WuXi Biologics operates a globally integrated service platform, encompassing research centers and manufacturing sites across multiple countries, including China, the United States, Ireland, Germany, and Singapore. The latest facility operates alongside 17 others in its network, supporting a comprehensive array of end-to-end solutions for global partners.

In addition to extensive drug product capabilities, WuXi Biologics leverages its advanced technologies, such as WuXiHigh™ and hyaluronidase co-formulation, to provide a full range of delivery formats. These include liquid and lyophilized vial formulations, pre-filled syringes, dual-chamber cartridges, as well as a diverse assortment of safety and automated combination products.

Focus on Sustainability and Innovation

Sustainability is at the forefront of WuXi Biologics' strategic goals. The company is dedicated to advancing sustainable growth initiatives while improving healthcare access. By integrating digital capabilities across the biopharmaceutical value chain, WuXi aims to enhance efficiency from development to manufacturing while adhering to exemplary Environmental, Social, and Governance (ESG) practices.

WuXi Biologics' commitment to innovation is crucial for overcoming evolving challenges in biologics manufacturing. By fostering collaboration with stakeholders and leveraging its robust CRDMO platform, the company addresses the ever-changing needs of its clients, ensuring timely and effective delivery of therapeutic biologics worldwide. As it prepares for continued growth and expansion, WuXi Biologics remains steadfast in its mission to empower healthcare professionals with advanced solutions for patient care and therapeutic development.

In conclusion, the launch of the DP15 facility marks an important step for WuXi Biologics in solidifying its role as a leading player in the biopharmaceutical manufacturing landscape, enabling the integration of drug substance production into high-quality drug product output seamlessly.